Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rivogenlecleucel - Bellicum Pharmaceuticals

Next Previous
Drug Profile

Rivogenlecleucel - Bellicum Pharmaceuticals

Alternative Names: Allogeneic polyclonal T-cells - Bellicum Pharmaceuticals; BPX-501; BPX-501 and AP1903; BPX-501-AP1903; BPX-501-rimiducid; BPX-501-T-cells; CaspaCIDe® DLI; Rimiducid activated BPX 501; Rivo-cel; Rivo-cel - Bellicum Pharmaceuticals

Latest Information Update: 09 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bellicum Pharmaceuticals
  • Class Cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Immunodeficiency disorders
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase I/II Haematological malignancies; Immunodeficiency disorders
  • No development reported Haemoglobinopathies; Immunological disorders; Metabolic disorders

Most Recent Events

  • 05 Aug 2019 Rivogenlecleucel - Bellicum Pharmaceuticals is available for licensing as of 05 Aug 2019. https://www.bellicum.com/
  • 08 Jul 2019 Bellicum Pharmaceuticals anticipates submission of Marketing Authorisation Application (MAA) for regulatory approval in Europe
  • 08 Jul 2019 Updated efficacy data from a phase I/II trial in Haematological malignancies and Immunodeficiency disorders released by Bellicum Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top